TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06725758: A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Sponsor: Orion Corporation, Orion Pharma · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 315 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,003,620

Rescue Site Savings

+$1,326,340

Unlock Full NCT06725758 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06725758 Rescue Dossier →